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Background: Lipid dyshomeostasis has been linked to Alzheimer disease (AD).
Results: Lipidomic analyses of brain tissue fromAD patients reveal region-specific changes inmultiple bioactive lipids, some of
which are phenocopied in AD mouse models.
Conclusion: Lipid anomalies observed in AD may be linked to pathogenesis, including endolysosomal dysfunction.
Significance: This study highlights the hypothesis-generating potential of lipidomics and its applicability to other diseases.
Lipids are key regulators of brain function and have been
increasingly implicated in neurodegenerative disorders includ-
ing Alzheimer disease (AD). Here, a systems-based approach
was employed to determine the lipidome of brain tissues
affected by AD. Specifically, we used liquid chromatography-
mass spectrometry to profile extracts from the prefrontal cor-
tex, entorhinal cortex, and cerebellum of late-onset AD (LOAD)
patients, as well as the forebrain of three transgenic familial AD
(FAD) mouse models. Although the cerebellum lacked major
alterations in lipid composition, we found an elevation of a
signaling pool of diacylglycerol as well as sphingolipids in the
prefrontal cortex of AD patients. Furthermore, the diseased
entorhinal cortex showed specific enrichment of lysobispho-
sphatidic acid, sphingomyelin, the ganglioside GM3, and
cholesterol esters, all of which suggest common pathogenic
mechanisms associated with endolysosomal storage disor-
ders. Importantly, a significant increase in cholesterol esters
and GM3 was recapitulated in the transgenic FAD models,
suggesting that thesemice are relevant tools to study aberrant
lipid metabolism of endolysosomal dysfunction associated
with AD. Finally, genetic ablation of phospholipase D2, which
rescues the synaptic and behavioral deficits of an FADmouse
model, fully normalizes GM3 levels. These data thus unmask
a cross-talk between themetabolism of phosphatidic acid, the
product of phospholipase D2, and gangliosides, and point to a
central role of ganglioside anomalies in AD pathogenesis.
Overall, our study highlights the hypothesis generating
potential of lipidomics and identifies novel region-specific
lipid anomalies potentially linked to AD pathogenesis.
Alzheimer disease (AD)3 is a debilitating neurodegenerative
disorder that afflicts millions of adults worldwide and the main
cause of late life dementia. Three outstanding neuropathologi-
cal features were noted in the original analysis from Alois
Alzheimer, namely senile plaques, neurofibrillary tangles, and
lipid granule accumulation (1). Based on the available molecu-
lar and biochemical techniques of the ensuing years, plaques
and neurofibrillary tangles were viewed as consistent features
of the AD brain and thus more heavily studied than changes in
brain lipid metabolism (1). It is now common knowledge that
the major molecular component of senile plaques is aggregated
amyloid- (A), which is generated from the amyloid precursor
protein (APP) via the sequential cleavage of APP by -secretase
-site APP cleavage enzyme 1 (BACE1) and the -secretase
complex, which contains a catalytic component, presenilin 1 or
2 (PS1 or 2). Although rare autosomal dominant mutations in
APP and PS1 or 2 lead to early-onset familial AD (FAD) (2), the
majority of AD cases are classified as late onset AD (LOAD). A
major risk factor for LOAD is the E4 allelic variant of ApoE,
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which encodes a protein involved in cholesterol metabolism
and lipid transport (3). Importantly, a variety of genes have been
recently linked to LOAD through genomewide association
studies and are directly or indirectly connected to lipid metab-
olism or cellular membrane dynamics (4, 5).
Strong evidence now links ADwith aberrant lipid homeosta-
sis, in part for the following reasons (6, 7). First, neuronal lipid
composition regulates the trafficking and/or activity of the key
membrane-bound proteins controlling A levels, including
APP, BACE1, and presenilins. For instance, -secretase activity
is regulated bymembrane levels of cholesterol and sphingomy-
elin (SM) (8). Second, A exerts its cytotoxic effects primarily
by perturbing cellular membranes, in part by modulating the
activity of phospholipases, such as PLA2 (9), PLC (10), and
phospholipaseD2 (PLD2) (11). Third, lipids, such as ganglioside
GM1, modulate the pathogenic potential of A by affecting its
propensity to aggregate (12). It is thus clear that an in-depth
analysis of brain lipid composition changes in AD would pro-
vide a basis for further investigation of cell signaling and meta-
bolic pathways that are disrupted in AD. Advances in lipidom-
ics, particularly electrospray ionization-mass spectrometry,
have facilitated the precise profiling of lipid species within tis-
sues, including low abundance lipid classes that participate in
cell signaling and membrane trafficking (13). Several studies
focusing on defined families of lipids have made use of this
technology to analyze lipid composition from AD brain tissue,
showing changes in plasmalogen phosphatidylethanolamine
(pPE) (14), sulfatide (Sulf) (15), ceramide (Cer), galactosylcer-
amide (GalCer), cholesterol (16), and alkylacylglycerophospho-
choline (17).Our own study has shown that a specificmolecular
species of phosphatidic acid (PA) previously linked to neurode-
generation in the fly (18) accumulates in the forebrain of old
Swedish APP (swAPP) mice (11).
In this study, we present the lipidomic analysis of postmor-
tem brain tissue obtained from patients with LOAD, specifi-
cally regions that typically are either moderately (prefrontal
cortex, PFC) or severely (entorhinal cortex, ERC) affected in
AD as well as a control region (cerebellum, CRB) that is largely
unaffected by this disorder (19, 20). We also provide the lip-
idome of forebrain tissue obtained from three commonly used
transgenicmousemodels of FAD, namely (i) PSEN1M146V (PS1)
(21), (ii) the Swedishmutant of APPK670N,M671L (APP) (22), and
(iii) PS1-APP double transgenic (23) lines. Using a combination
of normal phase and reverse phase LC-MS approaches, we ana-
lyzed 26 different lipid subclasses including lysophospholipids,
glycerophospholipids, sphingolipids, glycerolipids, and sterols,
covering over 300 lipid species. Our data show that multiple
lipid subclasses are dysregulated in both the human AD tissue
and AD mouse models, uncovering novel lipid pathways that
may be linked to abnormal cellular activity and thus potential
targets for further studies.
EXPERIMENTAL PROCEDURES
Annotation of Lipid Species—Glycerophospholipids, lyso-
phospholipids, and diacylglycerol (DAG) were annotated as
lipid subclasstotal fatty acyl chain length:total num-
ber of unsaturated bonds. Sphingolipids were annotated as
lipid subclasssphinogoid base residue/fatty acyl res-
idue. Triacylglycerol (TAG) was annotated as TAG
total fatty acyl chain length:total number of unsaturated
bonds/fatty acyl residue). Cholesterol ester (CE) was
annotatedCEfatty acyl residue.
Human Brain Tissue—Frozen postmortem brain tissue sam-
ples were obtained from the New York Brain Bank at Columbia
University Medical Center. Three different brain regions were
sampled from different subjects: PFC, ERC, and CRB.Morpho-
logically, each dissected region consisted predominantly of gray
matter with minimal associated underlying white matter. AD
was defined as “high probability of AD” based onNIA, National
Institutes of Health-Reagan Institute (NIA-RI) criteria. Con-
trolswere free ofmajor neuropathological diagnoses, and either
did “not meet” or met “low probability of AD” by NIA-RI crite-
ria. Further sample information, including a semiquantitative
assessment of neuronal loss, neurofibrillary tangles, amyloid
neuritic plaques, and Lewy body burdens, for the PFC and ERC,
is presented in supplemental Dataset S3. On average, the ERC
exhibited higher levels of pathology than the PFC in LOAD
samples.
ADMouse Models—A mixed population of wild-type, PS1,
APP, and PS1-APP mice were described previously (21–24),
aged between 9 and 11.5 months, were used for full lipidom-
ics analysis in this study. An older group of wild-type and
APP mice aged between 14 and 15 months were used for
targeted PA analysis. SwAPP mice with the Pld2/ and
Pld2/ genotypes with an average age of 12 months were
described before (11) and used to examine the changes in
sphingolipids and cholesterol ester. All mice were sacrificed
by cervical dislocation, the forebrain dissected immediately
and frozen in liquid nitrogen before storage at80 °C.
Analysis of Lipids Using High Performance Liquid Chroma-
tography-Mass Spectrometry—Lipid extracts were prepared
using a modified Bligh/Dyer extraction procedure, spiked with
appropriate internal standards, and analyzed using an Agilent
1200 HPLC system coupled with an Applied Biosystem Triple
Quadrupole/IonTrapmass spectrometer (3200Qtrap). Further
cross-lab validation of our approach can be found in our previ-
ous work (25). Separation of individual lipid classes of polar
lipids by normal phaseHPLCwas carried out using a Phenome-
nex Luna 3 silica column (inner diameter 150 2.0mm) with
the following conditions: mobile phase A (chloroform:metha-
nol:ammonium hydroxide, 89.5:10:0.5), B (chloroform:metha-
nol:ammoniumhydroxide:water, 55:39:0.5:5.5); flow rate of 300
l/min; 5% B for 3 min, then linearly changed to 30% B over 24
min andmaintained for 5min, and then linearly changed to 70%
B over 5 min and maintained for 7 min. Then, the gradient was
changed back to the original ratio over 5 min and maintained
for 6 min for column re-equilibration. Multiple reaction mon-
itoring transitions were set up for quantitative analysis of vari-
ous polar lipids (26, 27). Individual lipid species were quantified
by referencing to spiked internal standards. PC, 14:0/14:0; PE,
14:0/14:0; PS, 14:0/14:0; PA, 17:0/17:0; PG, 14:0/14:0; d31-PI,
18:1/16:0; C8-GluCer, C17-Cer, C12-Sulfatide, and C12-SM
were obtained from Avanti Polar Lipids (Alabaster, AL).
Dioctanoyl phosphatidylinositol (PI, 16:0-PI) was used for lyso-
phosphatidylinositol quantitation and obtained from Echelon
Biosciences, Inc. (Salt Lake City, UT).
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TAG, DAG, and CE were analyzed using a modified version
of reverse phase HPLC-electrospray ionization-MS described
previously (28). Briefly, separation of TAG and CE from polar
lipids was carried out on an Agilent Zorbax Eclipse XDB-C18
column (inner diameter 4.6  150 mm) using an isocratic
mobile phase chloroform, methanol, 0.1 M ammonium acetate
(100:100:4) at a flow rate of 250l/min. TAGwere calculated as
relative contents to the spiked d5-TAG 48:0 internal standard
(CDN isotopes), whereas cholesterol esters were normalized to
corresponding d6-C18 cholesterol ester (CDN isotopes). DAG
species were quantified using 4-methyl 16:0 diether DAG as an
internal standard (Avanti Polar Lipids). Free cholesterol was
analyzed by reverse phase HPLC atmospheric pressure chemi-
cal ionization MS, utilizing the same XDB-C18 column as
above but with chloroform:methanol, 1:1 (v/v), as the mobile
phase at a flow rate of 500 l/min (29). The instrument was
operated in the positive mode with a vaporizer temperature of
500 °C and corona current of 3 A. Free cholesterol was quan-
tified relative to spiked d6-cholesterol (CDN isotopes) internal
standard.
Data Analysis and Presentation—Lipid levels for each sam-
plewere calculated by summing up the total number ofmoles of
all lipid species measured by all three LC-MS methodologies,
and then normalizing that total to mol %. The final data are
presented as mean mol % with error bars showing mean S.E.
All lipid species in the human samples andmore than 98%of the
lipid species measured in the mouse samples were found to
have equal variance (data not shown). For the human samples, a
two-tailed Student’s t test was used for statistical analysis. The
mouse data were analyzed by one-way analysis of variance fol-
lowed by post hoc multiple comparisons Tukey range test as
indicated accordingly. In all cases, *, p 0.05; **, p 0.01; ***,
p 0.001. For all bar graphs, error bars represent the mean
S.E.
RESULTS
Comparative Lipid Profiling of Postmortem Human Brain
Tissue—Postmortem brain tissues obtained from both control
andADpatients with similar average age, cold, and frozen post-
mortem intervals were used in our analysis (Table 1). Depend-
ing on brain region,44–48% of the lipidomemeasured in our
analysis was made up of free cholesterol (Fig. 1, supplemental
Fig. S1A and Dataset S1A). The next largest group is comprised
of the glycerophospholipids, the bulk of which is made up of
phosphatidylcholine (PC) (14.4–17.5%), phosphatidylethanol-
amine (PE) (4.0–6.3%), and pPE (8.0–9.8%). Other glycero-
phospholipids of intermediate abundance are phosphatidylser-
ine (PS) (2.5–4.2%), phosphatidylinositol (PI) (2.4%-2.8%), and
ether PC (ePC) (1.3%). Very low abundance glycerophospholip-
ids were also measured including lysophospholipids (0.84–
1.12% total), PA (0.16–0.25%), phosphatidylglycerol (PG)
(0.06–0.09%), and lyso-bisphosphatidic acid (LBPA) (0.013–
0.025%). In addition, we also measured a wide array of sphin-
golipids such as SM (7.7–9.5%), Cer (1.0–1.3%), glucosylcer-
amide (GluCer) (1.4–2.6%), GalCer (1.4–2.4%), ganglioside
GM3 (0.050–0.083%), and Sulf (1.1–2.1%). Comparatively,
glycerolipids such as DAG (0.33–0.62%) and TAG (0.05–
0.10%) and sterol derivative CE (0.31–0.62%) make up a very
small proportion of the entire lipidome. The detailedmolecular
distribution of the individual lipid species measured can be
found in supplemental Figs. S2–S4 and Dataset S1B. The PFC
and ERC had a similar fatty acyl chain profile, consistingmostly
of medium (36C) and long (38C) chain fatty acyls and with
either monounsaturated or polyunsaturated fatty acids with 4
or 6 bonds (Fig. 3, A, B,D, and E). Surprisingly, the CRB exhib-
ited a unique fatty acyl profile, with the highest proportion from
medium-chain length (36C) and monounsaturated phospho-
lipids (supplemental Fig. S1, B and C). However, all three brain
regions are highly similar in terms of sphingolipid chain length,
with the majority being long (42C) or medium (36C) chain
length (Fig. 3, C and F, and supplemental Fig. S1D).
Postmortem AD Tissue Display Region-specific Differences in
Lipid Metabolism—Overall, whereas the lipid profile of the
CRB from AD patients was comparable with that of control
subjects (supplemental Figs. S1 and S4), the lipid profiles of
both PFC and ERC were affected by the disease (Fig. 1). In the
PFC, the most striking change was observed for DAG, which
showed an overall 1.8-fold increase in AD (Figs. 1A and 4, and
supplemental Fig. S2 andDataset S1). Although numerous spe-
cies ofDAGwere up-regulated, a pool ofDAG (38:4) believed to
derive from the PLC-mediated cleavage of phosphatidylinositol
4,5-bisphosphate (PI(4,5)P2) and thus involved in signaling
(30), was up-regulated by 2.1-fold (supplemental Fig. S2).
Analysis of glycerophospholipids showed an overall decrease in
the levels of lysophosphatidylcholine (LPC) and lyso ether PC
(LPCe) (19 and 13%, respectively), but no changes in PC.
There was a clear decrease in total PE (25%), including major
PE species, 40:6, 38:6, and 38:4. Contrary to a previous report
(14), lower pPE levels were not seen except for a slight decrease
in a single species, PE, 38:6p. Specific pools of ePC, 34:0p, 34:1p,
and 32:1e, were up-regulated, whereas PC 34:0e was down-reg-
ulated. In the overall fatty acyl distribution, therewas a decrease
in long-chain fatty acids (40C) with a corresponding increase
in short-chain fatty acids (34C) (Fig. 3, A and B). Sphingolipid
metabolism was also perturbed in AD samples, with a 25%
decrease inmedium length species (Fig. 3C). Althoughmedium
length SM d18:0/20:0 and d18:1/20:0 were subtly down-regu-
lated, long-chain species SM d18:1/22:1 and d18:1/26:1 were
up-regulated. The overall Cer levels were increased by 33%,
TABLE 1
Average age at time of death, cold, and frozen postmortem intervals of patients used in this study
Prefrontal cortex Entorhinal cortex Cerebellum
Control AD Control AD Control AD
Number of samples 10 10 8 10 10 10
Age (yrs) 78.7 8.2 83.2 5.3 82.0 5.2 85.4 5.2 85.0 5.4 85.4 3.3
Cold PMI (h) 6.4 4.6 6.4 7.5 4.5 4.9 4.8 8.1 2.3 1.0 4.1 6.4
Frozen PMI (h) 15.0 15.1 19.2 11.0 20.3 7.8 18.2 8.2 18.8 8.2 16.3 6.5
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mostly due to themajor Cer species d18:1/18:0. However, there
was a clear metabolic shift toward an increase of simple glyco-
sphingolipids GluCer (43%) and GalCer (32%), perhaps
reflecting increased catabolism of Sulf (which were decreased
by25%) (see also Ref. 15).
The ERC tissue exhibited a different pattern of lipid altera-
tions compared with the PFC (Figs. 1B and 4, supplemental Fig.
S3 and Dataset S1). LBPA (also called bis(monoacylglyceryl)-
phosphate), a lipid that is synthesized primarily from PG and
highly enriched in the endolysosomal system (31), was highly
enriched in AD (1.8-fold), including numerous species such
as 32:1, 34:3, 36:3, 36:1, and 38:5 (supplemental Fig. S3). This
region also showed increased levels in multiple species of the
polyunsaturated lipid pools including PC 38:4p, 40:5p, and PE
36:5, 38:5, and 36:3p. Unlike the PFC, AD-affected ERC also
exhibited alterations in different subclasses of sphingolipids,
specifically increases in SM and ganglioside GM3 (20 and
64%, respectively). Strikingly, whereas SM species with a
shorter fatty acyl residue including d18:0/18:0, d18:1/16:1, and
d18:1/18:0 were selectively enriched, GM3 enrichment was
restricted mainly to those with longer chain fatty acyl residues
such as d18:0/24:0, d18:1/22:0, and d18:1/24:0 (supplemental
Fig. S3). The selective increase in higher abundance SM led to a
modest boost in overall short-chain sphingolipids distribution
(Fig. 3F). Last, levels of CE, i.e. lipids typically enriched in lipid
droplets (31), were significantly higher in ERC with AD (1.7-
fold), particularly in the form of CE-16:1, CE-16:0, andCE-18:1.
Interestingly, select pools of TAG (e.g. TAG 56:7(22:6) and
56:5(18:1)), which are also enriched in lipid droplets (32), accu-
mulated in AD-affected ERC (supplemental Fig. S3).
Comparative Lipid Profiling of FADMouseModels Forebrain
Brain Tissue—To determine whether any of the lipid changes
seen in LOAD are phenocopied in the brain of commonly used
mouse models of FAD, we characterized the forebrain lipid
composition ofWT, PS1,APP, andPS1-APPmicewithin an age
range (i.e. 9–11.5 months) where transgenic mice have been
FIGURE 1. Postmortem human brain tissue lipid composition is altered in LOAD. Various lipid changes are seen in PFC (A) and ERC (B) tissues. Lipid
subclasses are expressed as mean mol % of all lipid species measured with error bars indicating mean S.E. The sample size for each brain region analyzed is
shown in Table 1. The absolute level of individual lipid species is presented in supplemental Dataset S1.
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characterized for various biochemical, morphological, electro-
physiological, and behavioral phenotypes. Although the PS1
mice exhibit subtly increased A42 levels without noticeable
pathology (21), the APP mice show significantly elevated A
levels and develop numerous plaques between 9 and 13months
(22). Comparatively, A production is markedly increased in
the PS1-APPmice, which begin developing a severe plaque bur-
den by 6–7 months (23). Reflecting in part the severity of A
burden, synaptic and behavioral impairments are least appar-
ent in the PS1 mice and highly exacerbated in the PS1-APP
mice (23, 24).
The comprehensive lipid composition of the forebrain tissue
of the differentmice is shown in Fig. 2, supplemental Fig. S5 and
Dataset S2. As with the case of the human AD tissue, free cho-
lesterol levels occupied the bulk of the lipidome we measured.
The remainder of the WT mouse forebrain lipidome is com-
posed mainly of bulk glycerophospholipids such as PC (17.0%),
PE (9.0%), pPE (9.3%), PS (3.3%), PI (3.2%), and to a lesser extent
sphingolipids such as SM (5.0%), GluCer (1.8%), GalCer (1.3%),
and Sulf (1.6%). Contributing about 2% of the lipidome are low
abundance glycerophospholipids such as lysophospholipids
(0.56% total), ePC (0.52%), PA (0.52%), PG (0.16%), LBPA
(0.007%), sphingolipids including Cer (0.34%), and GM3
(0.069%), glycerolipids DAG (0.058%) and TAG (0.2%) and ste-
rol derivative CE (0.33%). The majority of phospholipids found
in themouse forebrain carry long-chain fatty acyls composed of
38 or more total carbon lengths, whereas medium (36C) and
short-chain (34C) length fatty acyls are less abundant (Fig.
3G). Corresponding to the long fatty acyl chain length, the
majority of the phospholipids are polyunsaturated with either 4
or 6 double bonds (Fig. 3H). Phospholipids with the monoun-
saturated bond are the third most abundant followed by fully
saturated phospholipids. Similar to the human brain tissue pro-
file, the majority of sphingolipid species are either long (42C)
or medium (36C) chain length (Fig. 3I).
Lipid Dysregulation in FAD Mouse Models—All three AD
transgenicmousemodels showeddistinctive lipid profiles com-
pared with the WT mice (Fig. 2, 4, supplemental Fig. S5 and
Dataset S2). Fatty acyl chain remodeling was evident, with an
overall decrease in long-chain phospholipid (C  40), and a
corresponding increase inmedium- to short-chain phospholip-
ids (C  36) (Fig. 3G). Related to these changes, a decrease in
fatty acyl chains carrying four polyunsaturated bonds was also
replaced by an increase inmonounsaturated and saturated fatty
acyls (Fig. 3H). In the APP and PS1-APP mice but not the PS1
mice, there was a similar decrease in long-chain sphingolipids
(C  40) that was balanced by increases in short and medium
length species (C	 36 to 38) (Fig. 3I).
In the PS1 mutants, there was a significant decrease in PS
(29%), PI (37%), PG (25%), and LBPA (29%) as well as in
LPC (13%) and LPCe (20%). Individual PA pools were also
highly dysregulated, with PA 34:1 and 36:1 having increasing
trends, whereas other species such as PA 32:1, 34:2, and 38:4
were decreased significantly (supplemental Fig. S5). Various
pools of the most abundant sphingolipid SM, such as SM d18:
1/18:0, and long-chain SM d18:1/26:1 and d18:0/24:0, were
selectively enriched. Unique to the PS1mutant was an increase
in long-chain GalCer species such as GalCer d18:1/24:1, d18:1/
24:0, and d18:1/26:0, which could be attributed to the degrada-
tion of Sulf (17%) (supplemental Fig. S5). Contrary to an ear-
lier study on PS1 mutant hippocampus (33), we found no
increase in Cer.
Similar to the other transgenicmice, theAPPmutant showed
decreased levels of PS (33%), PI (41%), PG (25%), LBPA
(43%), and LPE (20%) with an overall increase in PC
(10%). A decrease in variousmolecular species of PA (e.g. 32:1
and 34:2) was also observed. These data are in contrast to the
specific increase of PA 34:2 seen in a different strain of Swedish
APP transgenic mice that were also older in age (11). To deter-
mine whether this was an age-related phenomenon, we con-
ducted a targeted PA analysis of 14–15-month-oldAPPmice of
the same genetic background and found that PA 34:2, and to a
lower extent other molecular species of PA, were indeed ele-
vated in these mice relative to 9–11-month-old APP mice
FIGURE 2. Effects of FAD transgene expression on mouse forebrain lipid composition. Aberrant lipid homeostasis is evident in different FAD mice. Lipid
subclasses are expressed as mean mol % of all lipid species measured with error bars indicating mean S.E. (WT, n	 6; PS, n	 6; APP, n	 6; PS-APP, n	 6).
Statistical significance shown here was assessed by one-way analysis of variance analysis. The absolute level of individual lipid species is presented in
supplemental Dataset S2.
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(supplemental Fig. S6). Similar to the PS1 mutant, an increase
in SM was observed in APP mice, reflecting the selective accu-
mulation of medium-chain length SM d18:1/18:1, d18:1/18:0,
and d18:0/18:0. This may have resulted from either increased
catabolism of GluCer and/or Sulf, both of which showed signif-
icant decreases (10 and 26%, respectively). Finally, the APP
mice showed a trend for increasing total levels of GM3 and CE
as represented by specific molecular pools such as GM3 d18:1/
18:0 and CE-22:6 (supplemental Fig. S5).
The PS1-APP mutant forebrain was the most severely
affected, reflecting the additive or synergistic effects of the two
transgenes. Similar to both the PS1 and APP mice, there was a
major loss of lipids from the PS (28%), PI (37%), PG (25%),
and LBPA (29%) subclasses and a slight increase in overall PC
levels. Unlike the single transgenics, PS1-APP mice showed a
decrease in pPE 34:2, 36:2, 36:1, and 36:0 as well as an increase
in lysophospholipids, such as lyso-PS (LPS) (17%), lyso-PA
(LPA) (21%), and lyso-PE (LPE) (16%). The changes in sph-
ingolipid profile, specifically an increase in SM pools such as
SM d18:1/18:0 and other long-chain species, and significant
decrease in total Sulf (17%), also resemble the changes of the
other two mutants. However, two groups of lipid alterations
were prominent in the PS1-APP mice. First, there was an
enrichment of GM3 (1.7-fold), particularly with major spe-
cies GM3d18:0/18:0, d18:1/18:0, and d18:1/20:0 (supplemental
Fig. S5). Second, total CE levels was highly enriched (4.3-
fold), with a dramatic increase (11-fold) for specific species,
such as CE-22:6 (supplemental Fig. S5).
PLD2 Ablation Causes Normalization of GM3 Levels—Lip-
idomics can be harnessed to identify lipid pathways that are
specific to perturbations made to different biological systems
(34, 35). Combining our current data set with pharmacological
FIGURE 3. Altered fatty acid composition of postmortem human brain tissue in the PFC and ERC regions and of forebrain derived from FAD mouse
models. Independent analyses for changes in diacylglycerophospholipids (GP) andDAG chain length equal to the total number of carbon atoms in the sumof
fatty acid moieties (A, D, and G), GP and DAG saturation equal to the total number of double bonds in the sum of fatty acid moieties (B, E, and H), sphingolipid
(SL) chain lengths equal to the total number of carbon atoms in both long-chain base and fatty acid moieties (C, F, and I) are expressed as mol %.
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treatments or genetic models that affect pathophysiological
phenotypes of ADmay identify bona fide targets of the disease.
We recently reported that swAPP transgenic mice lacking
PLD2, which hydrolyzes PC to generate PA, are protected from
the synaptotoxic and memory-impairing actions of A in vitro
and in vivo (11). This protection occurs despite the production
of high amounts of A indicating that the toxic effects of A
may be neutralized. To understand the molecular basis of this
protection, we conducted a targeted lipidomic analysis of the
forebrain of these mice, which were slightly older than those
used in Figs. 2–4 (see “Experimental Procedures”). Although
most sphingolipid classes appear to be unaltered in the mutant
mice, profound alterationswere observed forGM3 andCE (Fig.
5A). In the Pld2/ only mice, most molecular species of GM3
were slightly reduced in the forebrain. In contrast, expression of
the swAPP transgene alone produced a significant increase in
GM3 and CE, similar to the PS1-APP animals (Fig. 2). Most
importantly, when swAPP expression and PLD2 ablation were
combined, GM3 but not CE levels were normalized, suggesting
that ganglioside metabolism may be correlated to the pathoge-
nicity associated with the swAPP model and its rescue in the
Pld2/ background (Fig. 5B).
DISCUSSION
In the present study, we conducted an in-depth lipidomic
analysis of AD brain tissue that covered over 300 lipid species
from 26 lipid subclasses. We observed that different regions of
the human brain undergo heterogeneous changes in lipid
metabolism in AD-affected patients. Although the CRB lipid
profile was largely unaffected, significant changes were
observed in the diseased PFC and ERC (Fig. 1 and supplemental
Fig. S1). Between these two tissues, the PFC seemed to carry
more severe lipid alterations, with decreased levels of LPC,
LPCe, and PE and elevated levels of Cer, GluCer, GalCer, and
DAG. In contrast, the ERC only showed significant increases in
LBPA, SM, GM3, and CE levels. However, there were also
numerous changes to individual lipid species in different sub-
classes, suggesting that fatty acid carbon chain specificity may
play an important role in AD pathogenesis (Fig. 4 and supple-
mental Figs. S2 and S3). In the PFC, this included various
molecular species from the ePC, SM, Sulf, andCE,whereas ERC
displayed variability in ePC, PE, and TAG. Importantly, the dif-
ferences in lipid signatures suggest that these two subregions
encounter different aspects or stages of AD pathogenesis, as
supported by functional and pathological analyses (19, 20). As
expected, neuronal loss was more obvious in the ERC than in
the PFC (supplemental Dataset S3). Because neuronal loss is
typically associated with gliosis, the lipidome of regions under-
going significant neuronal loss, such as the ERC, may reflect in
part changes in the neuron/glia ratio.
Because mouse models are used extensively to study AD
pathogenesis, we set out to define whether specific changes in
lipid metabolism in brain tissue with LOAD are phenocopied
by mouse models of FAD and if these pathways can be targeted
for further studies. Granted, this type of comparative analysis
faces inherent challenges, including species-specific differences
and disease etiology (i.e. FAD versus LOAD), and are thus not
expected to be a perfect model for studying LOAD.With these
caveats inmind, we observed dramatic lipid changes in all three
transgenics that were not seen in humans. Specifically, a variety
of anionic phospholipids and sphingolipids, such as Sulf, were
decreased in transgenic models. Furthermore, genotype-spe-
cific lipid changes were observed and in several cases, the alter-
ations present in the PS1-APP mice reflected an additive or
synergistic effect of bigenic FAD gene expression. For instance,
PS1-APP mice exhibited a striking elevation of CE and GM3,
which was present to a lower extent in the APPmice and virtu-
ally absent from PS1 mice (Fig. 2 and supplemental Fig. S5).
Our analysis points to dysregulation of specific lipids poten-
tially involved in key anomalies seen in AD including synaptic
dysfunction and neurotransmission deficits (36). For instance,
DAGmetabolism, which is highly aberrant in diseased PFC, has
been implicated in a number of synaptic processes including
the regulation of dendritic spine morphology, plasticity, and
neurotransmitter release (37). Importantly, overactivation of
PKC, a target of DAG, interferes with PFC-regulated working
memory (38), a key feature of AD. DAG accumulation in
FIGURE 4. Comparative lipid profile of LOAD human samples versus FAD transgene expressingmouse forebrains. The heat maps show all lipid species
measured and are organized according to phospholipids, sphingolipids, and neutral lipids classification. The PS, APP, and PS1-APP columns represent the
normalized values of the individual lipid species of mutant mice compared with wild-type mice, whereas the PFC, ERC, and CRB columns represent the
normalized values of the individual lipid species of LOAD patients compared with control patients for each tissue type. The color bars represent the log2 value
of the ratio of each lipid species and only statistically significant changes are shown (p  0.05). Statistical analysis for the mouse data is based on one-way
analysis of variance and post hoc Tukey range test.
FIGURE 5. PLD2 ablation normalizes GM3 levels in an AD mouse model
expressingSwedishAPPtransgene.A, theoverall sphingolipidandcholesterol
ester levels,andB, individualGM3species intheforebrainof thesemousemodels
are presented as mean mol % with error bars indicating mean S.E. (WT, no Tg,
n	 8; KO, no Tg, n	 6;WT, APP, n	 5; KO, APP, n	 6).
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the PFC likely occurs through A-stimulated hydrolysis of
PI(4,5)P2 by PLC (10), based on the specific accumulation of
polyunsaturated DAG 38:4 (supplemental Fig. S2), a primary
metabolite of PI(4,5)P2 (30). Compounding this effect may be
the loss of DAG kinase activity because synaptic targeting of
DAG kinase depends on PSD95, whose levels are decreased in
AD-affected brain tissue (11, 37). Furthermore, aberrant accu-
mulation of sphingolipids in the PFC may also contribute to
dysregulation of synaptic vesicle fusion and trafficking of
NMDA receptors (39). This may reflect the fact that A42 acti-
vates neutral sphingomyelinase, which produces Cer (8), and
that sphingolipid enzymes are significantly altered in this tissue
(40). Overall, our data suggest that aberrant DAG and sphingo-
lipid metabolism are likely to participate in synaptic dysfunc-
tion in diseased PFC.
Another important observation is the LBPA increase in dis-
eased ERC. LBPA is enriched specifically within late endo-
somes, where it plays a role in the biogenesis of multivesicular
bodies (41). The enrichment of LBPA is thus consistent with a
dysfunction of the late endosomes/multivesicular bodies. Aber-
rant endosomes have been previously reported in Down syn-
drome and AD (42) and growing evidence, most recently
through genome wide association (4, 5) and gene expression
(43) studies, indicates that defects in the endolysosomal path-
way are linked toAD.An emerging hypothesis in the field is that
defects in the endolysosomal pathway can affect amyloidogen-
esis, as organelles along this pathway contain high levels of APP
as well as functionally active pools of BACE1 and -secretase
(44, 45). Additionally, lysosomal defects alter the clearance of
autophagosomes, which are double-membrane organelles of
the autophagy pathway that mediate the elimination of protein
aggregates, including Tau (45). Notwithstanding other possible
functional implications (see below), the ERC accumulation of
SM, GM3, and CE adds strong support to the endolysosomal
dysfunctionhypothesis. Indeed, SMandGM3 trafficwithin and
between the plasma membrane and endosomes (46), whereas
intracellular CE, normally found in lipid droplets, has also been
detected in late endosomes (47). Of particular relevance, the
accumulation of SM and gangliosides impairs lysosomal degra-
dation of APP-CTFs, which enhances amyloidogenesis (48). A
likely secondary implication of SM and GM3 accumulation is
the propensity for ganglioside-enriched membrane microdo-
mains at the cell surface and in endosomes to seed A oligo-
merization (12). Taken together, the overall lipid profile
changes seen in the ERC of AD patients suggest a pathogenic
cascade that is reminiscent of lipid traffic jams described in
lipid storage diseases such asNiemann-Pick types A andC (49).
Although lipid changes in FAD models are in most aspects
vastly different from the LOAD samples, our lipidomic analysis
suggest that theAPP andPS1-APPmice are likely suitablemod-
els to study the role of ganglioside (GM3) and CE accumulation
inAD, particularly because these anomalies are also observed in
the ERC of AD patients (Fig. 4). A key question is whether the
reversal of these lipid changes can ameliorate the AD-relevant
phenotypes of the transgenicmodels, including enhanced amy-
loidogenesis. A partial answer, as well as an important “proof of
concept” validation of our analysis, is that the pharmacological
inhibition and genetic ablation of acyl-coenzyme A:cholesterol
acyltransferase 1, a CE-synthesizing enzyme, lower A produc-
tion and improves memory related tasks in transgenic models
of AD (32). Our own studies suggest that the protective role of
PLD2 ablation in APP transgenic mice may be related to gan-
gliosides, as suggested by the normalization of GM3 levels to
those found in controlmice (Fig. 5). This raises important ques-
tions about how PLD and its product PA are related to gangli-
oside metabolism and perhaps endolysosomal dysregulation in
AD (11, 50). Additionally, because PLD2 ablation mitigates the
signaling, but not the biogenesis ofA (11), we hypothesize that
the GM3 elevation observed in the APP models (which is cor-
rected in the Pld2 knock-out) occurs downstream of A. Inter-
estingly, the normalization of GM3 levels in the FAD mouse
lacking PLD2 occurs independently of CE, suggesting that CE
elevation in FAD mice may not be driven by increased A sig-
naling per se. Overall, our data suggest that there are multiple
ways to relieve lipid traffic jams that may be detrimental to
neural cells in AD pathogenesis.
Finally, our study suggests that AD is associated with a more
general perturbation of membrane properties. The length and
degree of saturation are important determinants ofmanymem-
brane characteristics including membrane thickness, fluidity,
local curvature, and molecular packing, which in turn regulate
the activities of membrane-bound enzymes (51). Intramem-
brane proteolysis is likely to be exquisitely regulated by mem-
brane thickness, withmajor implications for -secretase-medi-
ated cleavage of APP (52). Interestingly, FADmouse forebrains
and to a lower extent diseasedPFCandERC, exhibited a relative
increase in short-chain lipids that was accompanied by a reduc-
tion in polyunsaturated phospholipids (Fig. 3). Similar results
have been described in synaptosomal and detergent-resistant
membranes due to aging (53) and AD (54). It is well known that
long-chain polyunsaturated phospholipids display an aversion
to highly ordered lamellar microdomains, whereas short-chain
monounsaturated or saturated phospholipids interact favor-
ably with sphingolipids and cholesterol in lipid rafts (6, 55).
These features thus point to an increased propensity of mem-
branes from the AD-affected brain to form lipid rafts, which
may have consequences on the amyloidogenic processing of
APP (6, 7).
A fundamental challenge in understanding a complex disease
using a systems based approache, such as lipidomics, is the
identification of pathophysiologically relevant changes among
a myriad of changes. Here, we have capitalized on the exquisite
sensitivity of LC-MS to characterize the lipidomeof brain tissue
from AD-affected humans and commonly used FAD mouse
models. We describe novel region-specific lipid changes in
human AD tissue that may contribute to AD etiology. We also
identified overlaps in lipid dysregulation between mice and
humans, suggesting that the FADmousemodelmay be suitable
for the study of specific aspects of AD-associated lipid dysregu-
lation. Our data thus provides a frame of reference for lipids
that can be targeted for therapeutic interrogation either
through pharmacological or enzymatic manipulations, to
improve learning and memory in the context of AD. In partic-
ular, PLD2 isoform-specific inhibitors (56) may prove to be
valuable therapeutic agents inADand thus require further eval-
uation. Our study also provides further incentive to systemati-
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cally analyze the various animal models of AD available in the
biomedical community as well as to expand these types of pro-
filing to other AD-vulnerable brain regions, so that a better
understanding of AD-linked lipid dysfunction can be achieved.
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